Drop Two, Add One: Vertex Adjusts Adaptive Trial Seeking An All-Oral HCV Regimen
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Vertex Pharmaceuticals, Inc., is adjusting an ongoing trial that tests its potential first-in-class protease inhibitor telaprevir in combinations it hopes will lead to an all-oral cocktail that is effective against genotype 1 hepatitis C, the firm announced Dec. 21.
You may also be interested in...
Merck May Be Positioned For First Approval Of A Protease Inhibitor In HCV
The pharma announced Jan. 6 that boceprevir has been accepted for priority review by FDA, making an early-May action date likely.
Vertex Braces For HCV Combo Paradigm With ViroChem Buyout
Takeover gives Vertex two clinical-stage polymerase inhibitors, and recalls Gilead’s key Triangle grab.
Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.